Cargando…

206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients

BACKGROUND: Serum lactate is included in the initial assessment of patients with sepsis. However, cancer patients develop lactic acidosis for a variety of reasons and are underrepresented in most studies. Therefore, elevated lactate levels may lead to overdiagnosis of sepsis and excessive antibiotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Suji, Whitman, Leah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776626/
http://dx.doi.org/10.1093/ofid/ofaa439.250
_version_ 1783630727049379840
author Mathew, Suji
Whitman, Leah
author_facet Mathew, Suji
Whitman, Leah
author_sort Mathew, Suji
collection PubMed
description BACKGROUND: Serum lactate is included in the initial assessment of patients with sepsis. However, cancer patients develop lactic acidosis for a variety of reasons and are underrepresented in most studies. Therefore, elevated lactate levels may lead to overdiagnosis of sepsis and excessive antibiotic use. The purpose of this study is to evaluate the utility of lactate as a biomarker for sepsis in cancer patients. The primary endpoint is the rate of 24-hour lactate clearance between infectious and non-infectious causes of lactic acidosis in cancer patients. Secondary objectives explore the duration of antibiotic therapy (DOT), the impact of liver metastasis on serum lactate levels, and the role of procalcitonin in distinguishing between infectious and non-infectious causes of lactic acidosis. METHODS: Retrospective chart review by Antimicrobial Stewardship team Figure 1: Study design [Image: see text] RESULTS: Preliminary data from a random subset of our sample (45/150) suggests there is no difference in mean serum lactate levels between infectious and non-infectious groups (4.6 vs 6.4). However, a substantial difference exists in the rate of 24h lactate clearance, although the difference was not statistically significant (58.3% vs 33%; p=0.13) (Fig2). There was a significant difference in antibiotic DOT (12.6 vs 3.3; p< 0.0001) presumably due to robust antimicrobial stewardship practices. Consistent with previous studies, there was a significant difference in procalcitonin levels between groups (27.2 vs 1.5, p=0.04). A sub-analysis of non-infectious patients with liver metastasis revealed a statistically significant difference in the rate of lactate clearance (21% vs 61.5%, p=0.03) (Fig3) suggesting that liver involvement impacts lactate clearance. Antibiotic DOT were also longer in non-infectious patients with liver metastasis (4.53 vs 1.38, p=0.02). Comparing end points between cancer patients with and witthout infection. [Image: see text] Liver involvement affecting Lactate clearance in patients without infection. [Image: see text] CONCLUSION: Cancer patients often manifest SIRS criteria at baseline which may lead to the overdiagnosis of infection and excessive antibiotic usage. Our observation is that lactate clearance as opposed to degree of lactic acidosis may be a more accurate indicator of infection in cancer patients especially those with liver involvement. This information may mitigate unnecessary antibiotic use in cancer patients with persistent lactic acidosis unrelated to infection. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776626
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77766262021-01-07 206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients Mathew, Suji Whitman, Leah Open Forum Infect Dis Poster Abstracts BACKGROUND: Serum lactate is included in the initial assessment of patients with sepsis. However, cancer patients develop lactic acidosis for a variety of reasons and are underrepresented in most studies. Therefore, elevated lactate levels may lead to overdiagnosis of sepsis and excessive antibiotic use. The purpose of this study is to evaluate the utility of lactate as a biomarker for sepsis in cancer patients. The primary endpoint is the rate of 24-hour lactate clearance between infectious and non-infectious causes of lactic acidosis in cancer patients. Secondary objectives explore the duration of antibiotic therapy (DOT), the impact of liver metastasis on serum lactate levels, and the role of procalcitonin in distinguishing between infectious and non-infectious causes of lactic acidosis. METHODS: Retrospective chart review by Antimicrobial Stewardship team Figure 1: Study design [Image: see text] RESULTS: Preliminary data from a random subset of our sample (45/150) suggests there is no difference in mean serum lactate levels between infectious and non-infectious groups (4.6 vs 6.4). However, a substantial difference exists in the rate of 24h lactate clearance, although the difference was not statistically significant (58.3% vs 33%; p=0.13) (Fig2). There was a significant difference in antibiotic DOT (12.6 vs 3.3; p< 0.0001) presumably due to robust antimicrobial stewardship practices. Consistent with previous studies, there was a significant difference in procalcitonin levels between groups (27.2 vs 1.5, p=0.04). A sub-analysis of non-infectious patients with liver metastasis revealed a statistically significant difference in the rate of lactate clearance (21% vs 61.5%, p=0.03) (Fig3) suggesting that liver involvement impacts lactate clearance. Antibiotic DOT were also longer in non-infectious patients with liver metastasis (4.53 vs 1.38, p=0.02). Comparing end points between cancer patients with and witthout infection. [Image: see text] Liver involvement affecting Lactate clearance in patients without infection. [Image: see text] CONCLUSION: Cancer patients often manifest SIRS criteria at baseline which may lead to the overdiagnosis of infection and excessive antibiotic usage. Our observation is that lactate clearance as opposed to degree of lactic acidosis may be a more accurate indicator of infection in cancer patients especially those with liver involvement. This information may mitigate unnecessary antibiotic use in cancer patients with persistent lactic acidosis unrelated to infection. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776626/ http://dx.doi.org/10.1093/ofid/ofaa439.250 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Mathew, Suji
Whitman, Leah
206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients
title 206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients
title_full 206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients
title_fullStr 206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients
title_full_unstemmed 206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients
title_short 206. The Utility of Lactate as a Biomarker for Sepsis in Cancer Patients
title_sort 206. the utility of lactate as a biomarker for sepsis in cancer patients
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776626/
http://dx.doi.org/10.1093/ofid/ofaa439.250
work_keys_str_mv AT mathewsuji 206theutilityoflactateasabiomarkerforsepsisincancerpatients
AT whitmanleah 206theutilityoflactateasabiomarkerforsepsisincancerpatients